姓名：赵龙
职称：讲师
电子邮箱：zhaolong@ntu.edu.cn
个人简介：
赵龙，男，陕西宝鸡市人。2012年本科毕业于兰州大学生命科学学院生物科学国家基地班, 获理学学士学位。2020年于兰州大学基础美高梅MGM33999生物化学与分子生物学专业, 获理学博士学位，导师王锐院士。2020年9月入职美高梅MGM33999从事教学科研工作。
科研经历：研究生期间，在甘肃省新药临床前重点实验室王锐院士团队，从事非天然氨基酸修饰的神经肽类药物设计和合成、构-效关系、及药理学活性研究相关课题。入职美高梅MGM33999以来，在美高梅MGM33999陈罡教授团队，以免疫检查点程序性细胞死亡蛋白1（PD-1）为靶点，构建一系列全新镇痛（抗抑郁）类小分子多肽，以期筛选出具有临床应用前景的先导化合物，用于多肽新药的研发。
专业研究领域：慢性疼痛及情绪障碍、镇痛（抗抑郁）类多肽药物
发表论文（按年度）：
1. Zhao L, Ma Y, Song XF, Wu YJ, Jin PJ, and Chen G*. PD-1: A New Candidate Target for Analgesic Peptide Design.J Pain. 2023, 24(7):1142-1150. (IF2022 = 4.0)
2. Zhang YH1, Sang R1, Bao JY1, Jiang ZH, Qian DN, Zhou Y, Su WF, Wei JH, Zhao L, Wei ZY, Zhao YY, Shi MX, and Chen G*. Schwann cell-derived CXCL2 contributes to cancer pain by modulating macrophage infiltration in a mouse breast cancer model.Brain Behav Immun. 2023, 109:308-320. (IF2022 = 15.1)
3. Zhao L1, Luo H1, Ma Y, Zhu SZ, Wu YJ, Lu MX, Yao XJ, Liu X, and Chen Gang*. An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects. Proceedings of the National Academy of Sciences. 2022, 119(31)e2204114119. (IF2022 = 11.1)
4.Yang RY1, Zhao L1, Bao JY, Wu YJ, Xia PH, Pan JY*.Downregulation of Nck1 After Spinal Cord Injury in Adult Rats.Balkan Med J. 2022, 39(1):39-47. (IF2022 = 3.0)
5.Zhou JJ, Zhao L, Wei S, Wang Y*, Zhang XH, Ma MT, Wang KR, Liu X*, and Wang R*. Contribution of the μ opioid receptor and enkephalin to the antinociceptive actions of endomorphin-1 analogs with unnatural amino acid modifications in the spinal cord.Peptides. 2021, 141:170543. (IF2022 = 3.0)
6. Ma MT, Wang ZJ, Wang J, Wei S, Cui JM, Wang Y, Luo KY, Zhao L, Xin Liu*, and Rui Wang*. Endomorphin analog exhibited superiority in alleviating neuropathic hyperalgesia via weak activation of NMDA receptors.J Neurochem. 2020, 155(6):662-678. (IF2022 = 4.7)
7. ZhaoL, Luo KY, Wang ZJ, Wang Y*, Zhang XH, Yang DX, Ma MT, Zhou JJ, Cui JM, Wang J, Han CZY, Liu X*, and Wang R*.Design, synthesis, and biological activity of new endomorphin analogs with multi-site modifications.Bioorg Med Chem. 2020, 28(9):115438. (IF2022 = 3.5)
8.Cui JM, Zhao L, Wang ZJ, Ma MT, Wang Y, Luo KY, Wang LQ, Wei S, Zhang XH, Han CZY, Liu X*, and Wang R*. MEL endomorphins act as potent inflammatory analgesics with the inhibition of activated non-neuronal cells and modulation of pro-inflammatory cytokines.Neuropharmacology. 2020, 168:107992. (IF2022 =4.7)
9.Wang C, Guo MZ, Qi RP, Shang QY, Liu Q, Wang S, Zhao L, Wang R*, and Xu ZQ*. Visible-Light-Driven, Copper-Catalyzed Decarboxylative C(sp3)-H Alkylation of Glycine and Peptides.Angew Chem Int Ed Engl. 2018, 57(48):15841-15846. (IF2022 =16.6)
10. Liu X, Zhao L, Wang Y, Zhou JJ, Wang D, Zhang YX, Zhang XH, Wang ZJ, Yang DX, Mou LY, and Wang R*. MEL-N16: A Series of Novel Endomorphin Analogs with Good Analgesic Activity and a Favorable Side Effect Profile.ACS Chem Neurosci. 2017, 8(10):2180-2193. (IF2022 =5.0)
11.Wang Y, Yang JX, Liu X,Zhao L, Yang DX, Zhou JJ, Wang D, Mou LY, and Wang R*. Endomorphin-1 analogs containing α-methyl-β-amino acids exhibit potent analgesic activity after peripheral administration.Org Biomol Chem. 2017, 15(23):4951-4955. (IF2022 =3.2)
12. Wang Y, Zhou JJ, Liu X, Zhao L, Wang ZJ, Zhang XH, Wang KZ, Wang LQ, and Wang R*. Structure-constrained endomorphin analogs display differential antinociceptive mechanisms in mice after spinal administration.Peptides. 2017, 91:40-48. (IF2022 =3.0)
13. Liu X, Zhao L, Wang Y, Mou LY, Zhang YX, Zhou JJ, and Wang R*. Design and Synthesis of a Novel Series of Opioid Dipeptides and Evaluation of Their Analgesic Effect in Vivo. Acta Chim. Sinica. 2016, 74:44-48. (IF2022 =2.5)
14.Liu XH, Zhang JL, Zhao L, Ma SX, Yang DX, Yan WJ, and Wang R*. Construction of Vicinal Tetrasubstituted Stereocenters with a C-F Bond through a Catalytic Enantioselective Detrifluoroacetylative Mannich Reaction.J Org Chem. 2015, 80(24):12651-8. (IF2022 =3.6)
15.Liu X, Zhao L, Wang Y, Mou LY, Yang JX, Zhang YX, Wang D, and Wang R*. Design, synthesis, and evaluation of new endomorphin analogs with enhanced central antinociception after peripheral administration.Bioorg Med Chem Lett. 2015, 25(22):5393-7. (IF2022 =2.7)
16.Wang Y, Liu X, Wang D, Yang JX, Zhao L, Yu J, and Wang R*.Endomorphin-1 analogues (MELs) penetrate the blood-brain barrier and exhibit good analgesic effects with minimal side effects.Neuropharmacology. 2015, 97:312-21. (IF2022 =4.7)
17. Sun QT, Li XY, Su JH, Zhao L, Ma MX, Zhu YY, Zhao YY, Zhu RR, Yan WJ*, Wang KR* and Wang R*. The Squaramide-Catalyzed 1, 3 -Dipolar Cycloaddition of Nitroalkenes with N - 2, 2, 2- Trifluoroethylisatin Ketimines: An Approach for the Synthesis of 5’-Trifluoromethyl-spiro [pyrrolidin-3, 2’-oxindoles]. Adv. Synth. Catal.2015;357:3187-3196. (IF2022 =5.4)
18. Ma MX, Zhu YY, Sun QT, Li XY, Su JH, Zhao L, Zhao YY, Qiu S, Yan WJ*, Wang KR*, and Wang R*. The asymmetric synthesis of CF3-containing spiro[pyrrolidin-3,2'-oxindole] through the organocatalytic 1,3-dipolar cycloaddition reaction.Chem Commun (Camb). 2015, 51(42):8789-92. (IF2022 =4.9)
19.Wang D, Liang JY, Feng JC, Wang KR, Sun QT, Zhao L, Li D, Yan WJ*, and Wang R*. The Quinine Thiourea-Catalyzed Asymmetric Strecker Reaction: An Approach for the Synthesis of 3-Aminooxindoles. Adv. Synth. Catal.2013, 355:548-558. (IF2022 =5.4)
专利成果（按年度）：
1. 赵龙，陈罡，包璟崟，潘静莹；“一种具有镇痛活性的PD-1靶向肽、其合成方法及其应用”，国家发明专利，授权专利号：ZL202110451639.1，授权日期：2022年07月05日；
2. 陈罡，赵龙，罗浩，杨日云，陆沐幸；“一类以PD-1受体为靶点的多肽化合物、其制备方法及应用”，国家发明专利，授权专利号：ZL202110651404.7，授权日期：2022年06月03日；
3. 王锐，王媛，刘鑫，赵龙；“多位点组合修饰的内吗啡肽类似物及其合成和应用”，国家发明专利，授权专利号：ZL201710067056.2，授权日期：2020年08月11日；
4. 王锐，刘鑫，赵龙，王媛；“一类双功能D-氨基酸修饰阿片肽类化合物及其合成方法与应用”，国家发明专利，专利申请号：CN201911188458.3，申请日期：2019年11月28日；
科研项目
1.主持的自然科学基金项目：
(1) 国家自然科学基金委青年科学基金项目(82101302), 靶向PD-1的小分子镇痛肽构建及活性研究, 2022.01.01-2024.12.31
(2)南通市基础科学研究计划 (JC2021113), 具有临床应用前景的PD-1靶向肽化学构建及活性研究，2021.06.01- 2023.06.01
2.参加的自然科学基金项目：
(1)国家自然科学基金委面上项目(32271054)，脊髓NG2细胞TLR2蛋白在神经病理性疼痛中的作用和机制研究, 2023.01.01-2026.12.31
(2) 国家自然科学基金委面上项目(81773566), 一种新型伤口愈合肽的设计及其在糖尿病足治疗中的应用研究, 2018.01.01-2021.12.31
讲授课程
医学细胞生物学、神经科学、神经生物学